Bristol Myers Squibb's facility in Devens, MA

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

Af­ter a long-await­ed ap­proval for its CD19 tar­get­ing CAR-T liso-cel, Bris­tol My­ers Squibb is gear­ing up for the loom­ing re­view of an­oth­er cell ther­a­py in its pipeline, ide-cel. Tak­ing not one but two CAR-Ts to mar­ket — and po­ten­tial­ly more — means Bris­tol will have to step on the gas to get its man­u­fac­tur­ing in or­der.

Look­ing to ad­dress that po­ten­tial road­block, Bris­tol will add a 244,000 square-foot cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty at its De­vens, MA site as it looks to grow its pro­duc­tion ca­pac­i­ty around liso-cel and, po­ten­tial­ly, ide-cel in the com­ing weeks, the drug­mak­er said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.